Bluebird's Zynteglo Gets EU Conditional Marketing Approval
Zacks Investment Research | Jun 04, 2019 04:16AM ET
bluebird bio, Inc. (NASDAQ:BLUE) announced that the European Commission (EC) has granted conditional marketing authorization to Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene), the company’s first gene therapy, for patients aged 12 years or older with transfusion-dependent β-thalassemia (TDT), who do not have a β0/β0 genotype and for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.
TDT is a severe genetic disease caused by mutations in the β-globin gene that result in reduced or absent hemoglobin.
Shares of the company increased 20% year to date against the industry ’s decline of 0.5%.
Zynteglo was reviewed as part of the European Medicines Agency’s (EMA) Priority Medicines (PRIME) and Adaptive Pathways programs. These programs support the medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options.
The conditional marketing authorization is supported by efficacy and durability data from the phase I/II HGB-205 study and the completed phase I/II Northstar (HGB-204) study along with available data from the ongoing phase III Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies, and the long-term follow-up LTF-303 study, as of the data cut off on Dec 13, 2018.
Data from phase I/II HGB-205 showed that 75% of patients, who do not have a β0/β0 genotype, achieved transfusion independence, while in the phase I/II Northstar study, 80% achieved the same. In Northstar-2 study, 80% patients achieved transfusion independence.
The approval makes available a gene therapy for certain patients with TDT that has the potential to transform lives by offering the possibility of a transfusion-free future.
The approval will boost sales for the company.
Zacks Rank and Other Stocks to Consider
bluebird currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Anika Therapeutics Inc. (NASDAQ:ANIK) , Applied Genetics Technologies Corp. (NASDAQ:AGTC) and Acorda Therapeutics Inc. (NASDAQ:AXGT) . All of them carry a Zacks Rank #1 (Strong Buy). You can see .
Get The News You Want
Anika’s earnings per share estimates have moved up from $1.22 to $1.28 for 2019 and from $1.21 to $1.33 for 2020 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters, with average beat of 72.00%.
Applied Genetics’ loss per share estimates have narrowed from $1.25 to 1 cent for 2019 and from $2.39 to $2.15 for 2020 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average beat of 83.47%.
Acorda’s loss per share estimates have narrowed from $3.84 to $3.59 for 2019 and from $3.32 to $3.09 for 2020 in the past 60 days. The company delivered a positive earnings surprise in all of the trailing four quarters, with average beat of 79.32%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.